Investor Webinar
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that Nigel Theobald, Chief Executive Officer, will provide a strategic update on the Company's ongoing development of Nuvec® as a delivery system for RNA therapeutics on Tuesday, 22 July 2025 at 10.00 am via the Investor Meet Company Platform.
Nigel will be joined by members of the Senior Leadership Team, including Dr Mark Edbrooke, Head of Strategy, who will present on The RNA Therapeutics Revolution, and Dr Fiona McLaughlin, Head of Research and Development, who will present on Established Delivery Platforms and the Key Benefits of Nuvec®.
Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Submit your questions directly to the management team via the N4 Pharma Investor Hub | Via N4 Pharma Investor Hub: investors.n4pharma.com https://n4pharma.com/link/eW32ae |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896 |
About N4 Pharma
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with commercial partners.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.